{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-23-000052","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2023-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.370401+00:00","generated_at":"2026-06-10T01:08:51.515449+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"QuidelOrtho preliminary Q3 revenue $738-744M; beats on early respiratory demand","bullets":["Total revenue $738-744M vs prior expectations; non-respiratory $557-560M, respiratory $181-184M.","Earlier-than-expected flu and COVID demand drove respiratory product sales higher in the quarter.","Full-year 2023 guidance maintained: rev $2.88-3.08B, adj EPS $4.85-5.30, adj EBITDA $800-830M.","All regions including China met or exceeded expectations; Q3 full results to be reported Nov 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-23-000052","json":"https://secwatch.observer/filing/0001906324-23-000052.json","markdown":"https://secwatch.observer/filing/0001906324-23-000052.md","text":"https://secwatch.observer/filing/0001906324-23-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000052/0001906324-23-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000052/qdel-20231012.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:08:51.515449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c8f12a874e6c1a8520f6a7fc26c7575744edc99","claim":"QuidelOrtho Corp reported fiscal third quarter ended October 1, 2023 results: revenue $738 million to $744 million. Guidance reaffirmed.","evidence_excerpt":"October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu. Third Quarter 2023 Preliminary Unaudited Revenue Results • Total revenues of $738 million to $744 million; • Non-respiratory product revenue of $557 million to $560 million; and • Respiratory product revenue of $181 million to $184 million. “Our strong performance in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000052/0001906324-23-000052-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal third quarter ended October 1, 2023"},{"label":"Revenue","value":"$738 million to $744 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}